The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Abstral 400 microgram sublingual tablets

400 microgram(s) Sublingual tablet

Kyowa Kirin Holdings B.V.PA2288/004/005

Main Information

Trade NameAbstral 400 microgram sublingual tablets
Active SubstancesFentanyl
Strength400 microgram(s)
Dosage FormSublingual tablet
Licence HolderKyowa Kirin Holdings B.V.
Licence NumberPA2288/004/005

Group Information

ATC CodeN02AB Phenylpiperidine derivatives
N02AB03 fentanyl


Licence Issued22/05/2009
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 1988 (S.I. No. 328 of 1988), as amended.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - HCP

Educational Materials - Patient

« Back